Compassionate Use of Sorafenib in Primary Resistant Severely Progressed FLT3-ITD Positive AML in a Young Woman - A Danish Case Report
Abstract
Acute myelogenous leukemia is a heterogeneous group of malignant diseases with high mortality. A continuous effort is being made in the attempt to find and describe the effects of novel treatment options and in recent years targeted therapy towards specific abnormalities in the malignant cell has increased. In this case report we describe the effect of FLT3-ITD targeting in the compassionate treatment of a primary resistant severely progressed FLT3-ITD positive AML in a young woman.
doi:10.4021/jh30w